Cough, Cold and Allergy (Hay Fever) Remedies

During the past few years, Slovenia has experienced a virtually non-existent flu season due to the outbreak of COVID-19. This led to individuals opting to stay at home and, when going out in public, adhering to practices like wearing face masks,…

Although the threat from COVID-19 is largely perceived to have past, many consumers continue to worry about how people will react if they sneeze or cough in public. Volume growth of cough, cold and allergy (hay fever) remedies is helping to drive the…

Most cough, cold and allergy (hay fever) remedies categories in Hungary are set to expand in volume terms in 2023 or record slower rates of decline than in 2022. Similar to the case with analgesics, the need for these products has been bolstered by…

Price sensitivity among Bulgarian consumers is a key factor influencing their purchasing decisions when it comes to cough, cold, and allergy (hay fever) remedies. As the minimum wage in Bulgaria is just under EUR400 in 2023, a significant portion of…

In Slovakia, cough, cold and allergy (hay fever) remedies was characterised by very strong increases in retail volume sales of OTC remedies for sore throats, coughs and colds. The high demand was the result of extremely high morbidity throughout the…

Cough, cold and allergy (hay fever) remedies is seeing slower growth in 2023 due to a shorter cold season caused by milder winter 2022/2023. The exception is antihistamines, which continues to grow at a solid rate due to high consumer demand amidst…

2023 marks the year when the cough and cold landscape is set to lose its uplift due to COVID-19, returning to a level closer to that seen pre-pandemic. Sales have continued to benefit from harsh seasonal colds and the flu season of 2022-2023.…

Cough, cold and allergy (hay fever) remedies in Latvia is registering moderate growth in 2023 as the category begins to stabilise post-pandemic. Retail value sales rebounded strongly 2022 after two years of decline, with lifestyles shifting back to…

Analgesics is expected to register moderate constant value growth in 2023. Though there was widespread severe flu in early 2023, cough and cold remedies are not expected to benefit to a huge degree, as most of these patients were hospitalised or put…

In 2022, cough, cold and allergy (hay fever) remedies was marked by increases in demand for products to soothe sore throat and cough complaints. This development was a result of extremely high morbidity throughout the year. In the first half of 2022,…

Following the return to normality in the wake of the COVID-19 crisis, with no more lockdowns or movement restrictions, there has been an increase in the spread of cold and flu viruses, as well as a widespread rise in issues caused by hay fever and…

The majority of subcategories within cough, cold and allergy remedies recorded positive growth in retail volume terms in 2023. This was due, in a large part, to a return pre-pandemic lifestyles, which facilitated the spread of the influenza virus and…

Whilst the category continues to record growth in 2023, the particularly high growth level seen in the previous year could not be maintained. 2022 was a strong year for the category as consumers returned to their pre-pandemic lifestyles following the…

During the last couple of years, the flu season was virtually non-existent as a result of Croatians staying at home and, when venturing out in public, wearing face masks, maintaining social distance and frequently washing their hands. This…

Cough, cold and allergy (hay fever) continues to rebound following the declines during the COVID-19 pandemic and the slow recovery in its aftermath. Unit prices have been driven up by inflation resulting in double-digit current value growth in 2023,…